/ Print /

IN THE PIPELINE

3 new FDA drug approvalsFDA recently approved 3 major drugs to treat lung cancer, prostate cancer, and cystic fibrosis. Here are the top 3 new drug approvals.
Patient group pushes FDA to improve biosimilar educationFDA should provide better education about biosimilar drugs on the agency’s web site dedicated to biosimilars, a patient advocacy group said.
Device restores vision to patient with Stargardt diseaseAn artificial vision device (MyEye, OrCam) has helped a blind veteran regain his independence, according to the charity Scottish War Blinded.
Opioid prescription limits gain supportA pharmacist organization is among the supporters of a new Medicare Part D proposal, which calls for a 7-day supply limit on opioid prescriptions.
DEA tightens fentanyl schedulingDue to the increased use of illicit fentanyl mixed with heroin and used in counterfeit prescription drugs, the DEA placed all illicit fentanyl analogues not already regulated by the Controlled Substances Act into Schedule I.
Glaucoma 'renaissance' builds from expanding surgical optionsUntil now, surgery has been considered a second-line treatment after medication and lasers because of the risks associated with trabeculectomy and tube shunts. Now ophthalmologists can draw from a larger surgical tool chest, explains Iqbal Ike K. Ahmed, MD.
Ophthalmologists called upon to help impaired colleaguesOphthalmologists must take an active role in preventing impaired colleagues from hurting patients, according to Terri Pickering, MD.
How advances in phaco benefit glaucoma surgeryAdvances in phacoemulsification are creating new opportunities for glaucoma surgery, especially in developing countries, according to Alan S. Crandall, MD.
Shaffer Prize report goes down one path, but leads to anotherResearch aiming to elucidate the underlying factors for oxidative damage to the trabecular meshwork in glaucoma has led to studies of alterations in gene expression that may ultimately guide the development of genetic therapy for glaucoma, said Carla J. Siegfried, MD, recipient of the 2018 Shaffer Prize for Innovative Glaucoma Research.
What advent of MIGS means for earlier glaucoma interventionIn addition to making use of MIGS, interventional glaucoma might utilize other novel drainage devices and sustained drug-delivery devices and be combined with cataract surgery. This approach is more proactive, aims at lower IOP, lowers risk and addresses adherence, said Iqbal Ike K. Ahmed, MD.